Scynexis (SCYX) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Scynexis (SCYX) Tops Q3 EPS by 2c
November 12, 2015 8:31 AM EST
JERSEY CITY, N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the initiation of a Phase 1 clinical trial to study the intravenous (IV) formulation of SCY-078. SCYNEXIS' novel antifungal drug candidate SCY-078 is in development as both an oral and IV formulation for the treatment of invasive and life-threatening fungal infections. The study will evaluate the safety, tolerability and pharmacokinetics of single-rising IV doses of SCY-078 in healthy subjects.
"SCY-078 has the potential to address key unmet needs in the treatment of invasive fungal infections, and this... More
November 12, 2015 8:30 AM EST
JERSEY CITY, N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the initiation of a Phase 1 clinical trial to study the intravenous (IV) formulation of SCY-078. SCYNEXIS' novel antifungal drug candidate SCY-078 is in development as both an oral and IV formulation for the treatment of invasive and life-threatening fungal infections. The study will evaluate the safety, tolerability and pharmacokinetics of single-rising IV doses of SCY-078 in healthy subjects.
"SCY-078 has the potential to address key unmet needs in the treatment of invasive fungal infections, and this... More
